期刊
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 299, 期 8, 页码 914-924出版社
AMER MEDICAL ASSOC
DOI: 10.1001/jama.299.8.914
关键词
-
Context The erythropoiesis- stimulating agents ( ESAs) erythropoietin and darbepoetin are licensed to treat chemotherapy- associated anemia in patients with nonmyeloid malignancies. Although systematic overviews of trials have identified venous thromboembolism ( VTE) risks, none have identified mortality risks with ESAs. Objective To evaluate VTE and mortality rates associated with ESA administration for the treatment of anemia among patients with cancer. Data Sources A published overview from the Cochrane Collaboration ( search dates: January 1, 1985- April 1, 2005) and MEDLINE and EMBASE databases ( key words: clinical trial, erythropoietin, darbepoetin, and oncology), the public Web site of the US Food and Drug Administration and ESA manufacturers, and safety advisories ( search dates: April 1, 2005- January 17, 2008). Study Selection Phase 3 trials comparing ESAs with placebo or standard of care for the treatment of anemia among patients with cancer. Data Extraction Mortality rates, VTE rates, and 95% confidence intervals (CIs) were extracted by 3 reviewers from 51 clinical trials with 13 611 patients that included survival information and 38 clinical trials with 8172 patients that included information on VTE. Data Synthesis Patients with cancer who received ESAs had increased VTE risks ( 334 VTE events among 4610 patients treated with ESA vs 173 VTE events among 3562 control patients; 7.5% vs 4.9%; relative risk, 1.57; 95% CI, 1.31- 1.87) and increased mortality risks ( hazard ratio, 1.10; 95% CI, 1.01- 1.20). Conclusions Erythropoiesis- stimulating agent administration to patients with cancer is associated with increased risks of VTE and mortality. Our findings, in conjunction with basic science studies on erythropoietin and erythropoietin receptors in solid cancers, raise concern about the safety of ESA administration to patients with cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据